Four drug candidates targeting three indications, Breast Cancer, Chron’s Syndrome and NASH (nonalcoholic steatohepatitis), were presented by our students in the closing ceremony of the Scientific MBA's as a result of a year developing different intellectual properties for potential new treatments
This academic year 2018-2019, our students started the master programs with four different patents that protected potential compounds to become new treatments, two new small entities, one cell therapy and one small peptide. The target indication selected by our students for these projects after meeting with the principal researchers and the technology transfer office managers were breast cancer triple negative and luminal, the most aggressive type of breast cancer, Chron’s disease, with a new approach of the overall current therapies, and Nash (nonalcoholic steatohepatitis) due to the metabolic effects of one of them and the absence of actual treatment.
The thesis jury was composed by Andrea Sáez, Investment analyst at Asabys Partners, Maribel Berges, Entrepreneur in lifesciences and Juan R. Garcia, board Chairman at the Biotechnology Business Institute. The objective these presentations is to stablish the scientific and regulatory paths, preclinical and clinical, to develop these indications through the FDA and EMA further to launch approval and market access as well as developing the business model were the investments need and the, the valuation of the IP and the exit strategy for the return of the investment is established.
Once again, the master students defended those conclusions showing, on one hand the potential of our institutions to continue development early stage science and how scientific managers are key in those processes.
The Biotechnology Business Institute Direction thanks our innovation managers, Coordinators, Board of Professors and Jury for another excellent year of hard work and congratulations to all of our students for the excellent results obtained and the effort during the academic year.
We look forward to the next edition.
Learn more about Discover & Transfer
Learn more about Scientific MBAs